Ausgabe 1/2002
Inhalt (18 Artikel)
Anticancer Activity and Protein Phosphatase 1 and 2A Inhibition of a New Generation of Cantharidin Analogues
Jennette A. Sakoff, Stephen P. Ackland, Monique L. Baldwin, Mirella A. Keane, Adam McCluskey
Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice
Lisa Polin, Kathryn White, Juiwanna Kushner, Jennifer Paluch, Chiab Simpson, Susan Pugh, Matthew K. Edelstein, Stuart Hazeldine, Joseph Fontana, Patricia LoRusso, Jerome P. Horwitz, Thomas H. Corbett
Lack of in Vitro – in Vivo Correlation of a Novel Investigational Anticancer Agent, SH 30
Srinivasu Poondru, Ralph E. Parchment, Vivek Purohit, Patricia LoRusso, Jerome P. Horwitz, Stuart T. Hazeldine, Lisa Polin, Thomas Corbett, Bhaskara R. Jasti
Partial Circumvention of P-Glycoprotein-Mediated Multidrug Resistance by Doxorubicin-14-O-Hemiadipate
Olga V. Leontieva, Maria N. Preobrazhenskaya, Ralph J. Bernacki
Chemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome – Recall Following Different Chemotherapy Agents
Yuk Fung Hui, Francis J. Giles, Jorge E. Cortes
Phase I Study of JM-216 (an Oral Platinum Analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies
Suzanne Jones, John Hainsworth, Howard A. Burris III, Dana Thompson, Eric Raefsky, Valerie Johnson, Sharon Calvert, Cecile Bulanhagui, David Lebwohl, F. Anthony Greco
Phase I Clinical Trial of 5-Fluoro-Pyrimidinone (5FP), an Oral Prodrug of 5-Fluorouracil (5FU)
Patricia M. LoRusso, Sucharu Prakash, Antoinette Wozniak, Lawrence Flaherty, Mark Zalupski, Anthony Shields, Howard Sands, Ralph Parchment, Bhaskara Jasti
Phase I/II Study of Gemcitabine plus Vinorelbine in Non-Small Cell Lung Cancer
Emilio Esteban, Joaquin Fra, Norberto Corral, Miguel Valle, Juan Carrasco, Marian Sala, Javier Puerta, Enrique Estrada, Isabel Palacio, Jose Maria Vieitez, Jose Maria Buesa, Angel Jimenez Lacave
Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies
J.H.M. Schellens, B. Heinrich, M. Lehnert, M.E. Gore, S.B. Kaye, P. Dombernowsky, R. Paridaens, A.T. van Oosterom, J. Verweij, W.J. Loos, H. Calvert, N. Pavlidis, H. Cortes-Funes, J. Wanders, M. Roelvink, C. Sessa, K. Selinger, P.S. Wissel, T. Gamucci, A.R. Hanauske
Phase II Trial of Docetaxel Chemotherapy in Patients with Incurable Adenocarcinoma of the Esophagus
Elisabeth I. Heath, Susan Urba, John Marshall, Steven Piantadosi, Arlene A. Forastiere
A Phase II Trial of Pyrazine Diazohydroxide in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy – Southwest Oncology Group Study
Robert P. Whitehead, Joseph M. Unger, Lawrence E. Flaherty, Eric H. Kraut, Glenn M. Mills, Catherine E. Klein, Robert A. Chapman, Gary C. Doolittle, Neel Hammond, Vernon K. Sondak
Phase II Trial of Amonafide in Central Nervous System Tumors: A Southwest Oncology Group Study
Sarah A. Taylor, Cathryn Rankin, Jeannette J. Townsend, Johnny B. Craig, Ralph B. Vance, Dilip L. Solank, Thomas D. Brown, Kurt Jaeckle
The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: a Southwest Oncology Group Study
James K. Weick, John J. Crowley, Mohamed A. Hussein, Dennis F. Moore, Bart Barlogie
A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
David G. Pfister, John McCaffrey, Andrew J. Zahalsky, Gary K. Schwartz, Eric Lis, William Gerald, Andrew Huvos, Jatin Shah, Dennis Kraus, Ashok Shaha, Bhuvanesh Singh, Suzanne Wolden, Michael Zelefsky, Ilana Palgi
Phase II Trial of Topotecan by Continuous Infusion in Patients with Advanced Soft Tissue Sarcomas, a SWOG Study
G. Thomas Budd, Cathryn Rankin, Laura F. Hutchins, Lucas Wong, Paul J. Petruska, Karen Antman
Raltitrexed (Tomudex) Administration in Patients Failing Multiple Prior Chemotherapy Regimens in Advanced Colorectal Cancer: a Pilot Study
N. Tsavaris, C. Kosmas, M. Vadiaka, A. Kontos, M. Fotia, A. Angelopoulou, N. Vrizidis, M. Soulla, S. Sougioultzis, Ch. Koufos